738P Combined ipilimumab and nivolumab in previously treated patients with cancer of unknown primary: Results of the CheCUP trial
Maria Pouyiourou(German Cancer Research Center), A. Krämer(German Cancer Research Center), U.T. Hacker, B. Kubuschok(University of Augsburg), Thomas Ernst(Jena University Hospital), Bianca Kraft(German Cancer Research Center), A Stenzinger(Heidelberg University), Tilmann Bochtler(Heidelberg University), Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Stefan Delorme(German Cancer Research Center), C. Benedikt Westphalen(LMU Klinikum), P. Schuett(Oncoceutics (United States)), Timothy Wohlfromm(German Cancer Research Center), Thomas Hielscher(Ontario Institute for Cancer Research), H. Löffler(University of Mannheim), M. Bitzer(University of Tübingen), G. Huebner
Cited by 3
Related Papers
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
|The Lancet Oncology|2016|374
Characterization of the rapamycin-sensitive phosphoproteome reveals that Sch9 is a central coordinator of protein synthesis
|Genes & Development|2009|351
PD-1 Blockade in Anaplastic Thyroid Carcinoma
|Journal of Clinical Oncology|2020|349